(Corrects currency in first paragraph to pounds from dollars)
Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker’s COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm 15 million pounds ($20 million) upfront and an additional 35 million pounds plus other costs by the end of 2021.
Oxford Biomedica said in a statement that under the deal it would mass-produce the potential vaccine, AZD1222, for the novel coronavirus for a period of 18 months, which may be further extended by another 18 months into 2022 and 2023. ($1 = 0.7458 pounds) (Reporting by Pushkala Aripaka in Bengaluru; editing by Patrick Graham)
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.
Sign up for a free trial of our full service at https://www.breakingviews.com/trial and follow us on Twitter @Breakingviews and at www.breakingviews.com. All opinions expressed are those of the authors.